
Don's health care transparency fix, Hochul punts on spending cuts and other commentary
Health desk: Don's Health Care Transparency Fix
President Trump's 'executive order requiring 'radical' healthcare price transparency,' cheer Arthur B. Laffer & Cynthia A. Fisher at Fox News, 'will revolutionize healthcare.' It 'doubles down on his first-term hospital and health insurance price transparency rules requiring the publication of actual prices of care and coverage.' And it's needed: 'Only 21.1% of hospitals nationwide are fully complying with' Trump's first-term rules as the Biden team didn't 'meaningfully enforce' them. Health care 'is the only economic sector where consumers cannot see real prices before they buy,' and thus 'prices for the same care can range by 10 times, even at the same hospital.' 'Trump's new order increases enforcement to boost compliance' and 'requires actual prices — not estimates — so patients can shop with financial certainty.' It 'will finally make healthcare price transparency a reality.'
Eye on NY: Hochul Punts on Spending Cuts
New York's ''all-funds' budget, including federal aid, totals $254.4 billion, an increase of 4.5 percent or roughly double the inflation rate,' reports the Empire Center's Bill Hammond. Medicaid 'accounts for most of this year's new spending,' as the Legislature's addition 'hikes the state share to almost $45 billion, an increase of 18.6 percent.' Ignoring the risks, 'lawmakers approved an unusually large increase in spending.' Despite congressional plans to 'constrain federal Medicaid funding,' economic uncertainty and Trump actions that have cost the state an estimated $1.3 billion, the budget 'does not attempt to hedge against these threats.' Instead, Hochul and the Legislature say they will 'cut spending later in the year as necessary.'
Foreign desk: Now's the Time To Strike Iran
President Trump insists he'll 'accept nothing less than 'total dismantlement' of Iran's nuclear program,' notes Karen Elliott House at The Wall Street Journal. Yet 'the mullahs in Tehran will never agree to that,' and Trump may be tempted to accept 'something akin to the 'worst deal in history,' signed by President Obama in 2015.' Yet Iran has 'never been weaker,' so 'now is the time for a U.S.-Israeli strike to destroy Iran's nuclear capability.' Yes, that involves risks. But if Trump 'believes Iran can be trusted to execute a new pact, he hasn't done his homework. If he settles for anything short of total dismantlement, it will be the moral equivalent of Joe Biden's ignominious withdrawal from Afghanistan. Trust in his leadership will be gone.'
Advertisement
Libertarian: Souter's Odd Claim to History
The 'unusual reason' Justice David Souter, who died last week at 85, will be remembered, per Reason's Damon Root: 'the severe and enduring backlash that he inspired.' Named to the Supreme Court 'by Republican President George H.W. Bush, Souter quickly emerged as a consistent 'liberal' vote in high-profile cases about hot-button issues such as abortion and affirmative action.' Hence 'the battle cry of 'No More Souters' . . . whenever a Republican president had the chance to fill a Supreme Court vacancy. In practical terms, what that meant was 'no more judicial nominees without verifiable conservative credentials.'' Don't expect to soon see another justice who infuriates 'the political party that first championed him while greatly benefiting the political party that first opposed him.'
From the right: The 'Disparate Impact' Obscenity
'You may not know the ins and outs of disparate impact' — the federal doctrine on racism Trump has moved to uproot via executive order, but Christopher Caldwell explains at The Free Press that 'you've surely seen its effects': the end of on-the-job meritocracy, as that 'produces a lower-than-random number of protected minorities.' Good for the prez on taking 'another step toward uprooting the second constitution that has been in place since the passage of the 1964 Civil Rights Act.' The Civil Rights Act of 1991 'introduced disparate impact into black-letter U.S. law. It would have to be repealed to bring about the meritocracy Trump seeks.' But perhaps congressional 'minds are changing' since both parties see 'what a devastating weapon civil-rights law can be — and, indeed, always has been.'
— Compiled by The Post Editorial Board
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Apex Labs Granted Israel MoH Approval to Expand Phase 2b Macrodose Psilocybin PTSD Clinical Trial
Israel's Ministry of Health (MoH) approval to add additional sites to APEX SUMMIT-90 160 patient phase 2b macrodose clinical trial: Tel Aviv University (TAU)'s Institute for Psychedelic Research located at the Sagol Brain Institute (SGI) in Tel-Aviv Sourasky Medical Center. Be'er Yaakov Mental Hospital (Merhavim) Center for Psychedelic Studies. For more information or to register visit (Canada) and (Israel). VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- Apex Labs Ltd. (APEX or the Company), a pharmaceutical company transforming the standard of mental health care with psilocybin is pleased to announce the approval by the Israeli MoH and IRBs to open two additional clinical trial sites for SUMMIT-90. The trial is a double-blind, placebo controlled phase 2b study evaluating multiple doses of APEX-90, a psilocybin macrodose utilizing APEX's US patent pending capsule. APEX-90 is administered in-clinic with study-assisted psychotherapy for severe depression within diagnosed PTSD. Israel is facing a severe mental health crisis: 44% of adults report depression and 42% PTSD, far above the 8–13% depression and 6–10% PTSD rates seen in the US and Canada. This MoH approval leverages the expertise of TAU's renowned SGI and Merhavim Hospital, which both have a rich history of pioneering research in neurological sciences. Their cutting-edge facilities and teams profound understanding of PTSD dynamics are poised to add patient recruitment expertise. 'I am honoured to have been able to facilitate this new partnership; another example of building important bridges between Canada and Israel in innovative clinical research, which will result in advancing patient access to emerging treatments,' says Sharon J. Fraenkel, TAU Canada's CEO for Ottawa, Quebec, and Atlantic Canada, on behalf of the organization. 'As someone deeply connected to Israel, witnessing the toll of PTSD among my loved ones, I'm driven to lead research that brings hope and healing,' says Alysa Langburt, APEX's VP of Global Clinical Development. 'This marks more than a clinical milestone, it represents a fundamental step towards transforming the mental health landscape in Canada and Israel, where the need has never been greater. Through our incredible partnerships, we aim to catalyze a shift in access, care and outcomes for those suffering with PTSD.' "SUMMIT-90 offers a beacon of hope for the significant numbers suffering from PTSD in Canada and Israel,' says Tyler Powell, co-Founder and CEO of APEX. 'It underscores our commitment to global mental health innovation and our belief in the opportunity for clinically proven psilocybin therapies to transform mental health care.' About Apex Labs is a patient-driven pharmaceutical company focused on revolutionizing the standard of mental health care with psilocybin. APEX's strategy is two-pronged, clinical evaluation of drug assets alongside a robust Early Access Program. APEX recognizes and prioritizes Veterans as a patient base with the most severe unmet medical need. Visit for more information and follow APEX on LinkedIn, Twitter and Instagram. Forward-Looking StatementsThis release contains certain "forward-looking statements" and certain "forward-looking information" as defined under applicable Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "anticipate", "believe", "continue", "plans" or similar terminology. Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability to control or predict, that may cause the Company's actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out here in, including but not limited to: receiving authorization of Health Canada Dealers Licence; filing US provisional patent, the Company evaluating the safety and efficacy of APEX-52 (psilocybin) and APEX-90 (psilocybin) in treating depression in Veterans and patients with Post-Traumatic Stress Disorder; statements related to APEX-52 and APEX-90, including manufacturing, dosing, and trial details; statements made by the Company's executives with respect to Health Canada's Dealer's Licence and capsule patent filing; the Company's efforts around the Early Access Program; statements made relating to Canadian Veteran patients; approvals by the Israeli Ministry of Health and ethics; the inherent risks involved in the general securities markets; uncertainties relating to the availability and costs of financing needed in the future; the inherent uncertainty of cost estimates and the potential for unexpected costs and expenses, currency fluctuations; regulatory restrictions, liability, competition, loss of key employees and other related risks and uncertainties. The Company undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents managements' best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information. SOURCE Apex Labs Ltd. CONTACT: For further information: info@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


UPI
18 minutes ago
- UPI
Six more Madleen Gaza humanitarian activists deported from Israel
Six more activists from the Freedom Flotilla Gaza humanitarian aid mission aboard the Madleen boat were deported from Israel Thursday. Photo by Freedom Flotilla Coalition June 12 (UPI) -- Six more activists from the Freedom Flotilla Gaza humanitarian aid mission aboard the Madleen boat were deported from Israel Thursday. The Adalah civil rights center said six international activists Mark van Rennes of the Netherlands, Suyab Ordu of Turkey, Yasemin Acar of Germany, Thiago Avila of Brazil and Rva Viard and Rima Hassan both of France were being transported to Ben Guiron airport for deportation after being detained for 72 hours. Adalaha added that French nationals Pascal Maurieras and Yanis Mhamdi are the last remaining activists from the Madleen and are expected to be deported from Israel Friday. The Israeli Navy intercepted the Madleen while it was enroute to Gaza in international waters. Swedish activist Greta Thunberg was among the activists deported earlier this week. Eight of the activists challenged their detention while four waived their right to go before a judge and were deported immediately. Israel's Detention Review Tribunal found the naval blockade of Gaza is legal under Israeli law and therefore the activists were lawfully detained. The activists assert that their detention and deportations are violations of international law. According to the Adalah Center, the activists reported they were subjected to solitary confinement and their access to attorneys was restricted.
Yahoo
22 minutes ago
- Yahoo
FIRST ON FOX: High ranking DOJ official resigns post to run for attorney general in red state
FIRST ON FOX: Aaron Reitz, a top official in President Donald Trump's Department of Justice, has resigned his post in the administration to run for attorney general of Texas, entering what he is calling a "fight for the soul of Texas." Reitz, a former Marine and chief of staff to Sen. Ted Cruz, R-Texas, served in the Trump administration under U.S. Attorney General Pam Bondi as the assistant attorney general for the Office of Legal Policy. Following speculation of a possible run for Texas attorney general, one of the most powerful positions in the state, Reitz resigned his position with the DOJ on Wednesday and officially launched his campaign the day after. "If we lose Texas, we lose the Republic," Reitz said in a statement sent to Fox News Digital. 205 Arrested In Fbi Child Sex Operation, Patel And Bondi Announce "This is no time for half-measures or untested cowards," he said, adding, "We are in a fight for the soul of Texas, our nation, and Western civilization itself." Read On The Fox News App "As Attorney General, I'll use every ounce of legal firepower to defend President Trump, crush the radical Left, advance the America and Texas First agenda, and look out for everyday Texans," he said. This comes as current Texas Attorney General Ken Paxton is running in hopes of replacing incumbent Sen. John Cornyn, R-Texas, in one of the most hotly contested primary races of the year. Reitz pledged to partner with the Trump administration to "clean up the border catastrophe with mass deportations and enhanced border security, take down the Soros-backed district attorneys, obliterate woke indoctrination, expose and root out election fraud, and defend our Constitutional rights without apology." John Cornyn Scores Tim Scott Endorsement, But John Rich Calls Cornyn 'The Lindsey Graham Of Texas' Reitz touted his conservative bona fides, saying, "I've spent my entire career in the trenches with the toughest conservatives in America." He is likely to garner endorsements from some of the country's leading Republicans, with DOJ officials, including Bondi, giving him a string of fond farewells after he announced his departure. In an X post Bondi said: "I'm proud to have worked with @aaron_reitz at @TheJusticeDept. Aaron played a central role in our work to Make America Safe Again — his next chapter will surely contribute to @POTUS's mission, and I look forward to seeing what Aaron does next in his home state of Texas!" FBI Director Kash Patel also chimed in, saying "Aaron is a personal friend, great American, and a relentless advocate for law and order. Thanks for serving our country, now it's time to deliver on his next mission. Good luck." Bondi Announces One Of Largest Fentanyl Seizures In Us History Before serving in the Trump administration and on Cruz's staff, Reitz previously held the position of Texas Deputy Attorney General for Legal Strategy under Paxton. In December, Paxton spoke very highly of Reitz, saying, "he's a proven and effective fighter for our Constitution and American Values" who was "our 'offensive coordinator' leading my very aggressive Texas-v-Biden docket." Paxton said that while working in his office Reitz "spearheaded some of our agency's most consequential actions on border security, immigration, Big Tech, Covid, energy, the environment, and election integrity." Texas Republican state Senator Mayes Middleton, another pro-Trump conservative, is also running for attorney article source: FIRST ON FOX: High ranking DOJ official resigns post to run for attorney general in red state